Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/1997

01-09-1997

Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin

Authors: Tadashi Suzuki, Seiki Minamide, Tsutomu Iwasaki, Hirohisa Yamamoto, Hiroshi Kanda

Published in: Investigational New Drugs | Issue 3/1997

Login to get access
Metadata
Title
Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin
Authors
Tadashi Suzuki
Seiki Minamide
Tsutomu Iwasaki
Hirohisa Yamamoto
Hiroshi Kanda
Publication date
01-09-1997
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/1997
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1005862730941

Other articles of this Issue 3/1997

Investigational New Drugs 3/1997 Go to the issue

OriginalPaper

Phase II trial of topotecan in advanced gastric cancer: A Southwest Oncology Group study

OriginalPaper

Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS

OriginalPaper

Unusual central nervous system toxicity in a phase I study of N1N11diethylnorspermine in patients with advanced malignancy

OriginalPaper

Preclinical pharmacokinetic, antitumor and toxicity studies with CL-994 (N-acetyldinaline)

OriginalPaper

Matrix metalloproteinase inhibitors: Present achievements and future prospects

OriginalPaper

A phase II Southwest Oncology Group study of cisplatin and continuous infusion vinblastine in the treatment of advanced soft tissue sarcoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits